Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy

Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy

Anti-PD-1 and anti-PD-L1 immunotherapy has provided a new therapeutic opportunity for treatment of advanced-stage non-small cell lung cancer (NSCLC). However, overall objective response rates are approximately 15%–25% in all NSCLC patients who receive anti-PD therapy. Therefore, strategies to overco...

Full description

Bibliographic Details
Main Authors: Xiang Yan, Li Wang, Ran Zhang, Xingxiang Pu, Shuhong Wu, Lili Yu, Ismail M. Meraz, Xiaoshan Zhang, Jacqueline F. Wang, Don L. Gibbons, Reza J. Mehran, Stephen G. Swisher, Jack A. Roth, Bingliang Fang
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:OncoImmunology
Subjects:
immune checkpoint inhibitors
pd-1 blockage therapy
virotherapy
p53 gene therapy
lung cancer
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1376156

Internet

http://dx.doi.org/10.1080/2162402X.2017.1376156

Similar Items